Acute Ischemic Stroke Diagnosis and Treatment

Global Acute Ischemic Stroke Diagnosis and Treatment Market to Reach US$3.1 Billion by 2030

The global market for Acute Ischemic Stroke Diagnosis and Treatment estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Computed Tomography, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Magnetic Resonance Imaging segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$642.7 Million While China is Forecast to Grow at 4.8% CAGR

The Acute Ischemic Stroke Diagnosis and Treatment market in the U.S. is estimated at US$642.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$497.7 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Acute Ischemic Stroke Diagnosis and Treatment Market – Key Trends & Drivers Summarized

What Is Acute Ischemic Stroke and How Is It Diagnosed?

Acute ischemic stroke (AIS) occurs when a blood clot blocks a blood vessel in the brain, leading to reduced blood flow and potential brain damage. It is one of the leading causes of disability and death worldwide, requiring rapid diagnosis and treatment to minimize long-term damage and improve patient outcomes. Diagnosis typically involves neuroimaging techniques such as computed tomography (CT) scans or magnetic resonance imaging (MRI) to detect blockages and assess the extent of brain injury. The early identification of stroke symptoms and timely diagnosis are crucial for initiating life-saving treatments, such as thrombolysis (clot-busting drugs) or mechanical thrombectomy, which aim to restore blood flow to the brain.

What Are the Latest Advancements in Stroke Treatment?

Recent advancements in the treatment of acute ischemic stroke have significantly improved patient outcomes, particularly through the development of mechanical thrombectomy devices and improved thrombolytic therapies. Mechanical thrombectomy involves the use of specialized devices to physically remove clots from the brain, and it has become a standard treatment for patients with large vessel occlusions (LVOs). New generations of clot retrieval devices are more effective, increasing the success rate of procedures and reducing complications. Thrombolytic drugs, such as tissue plasminogen activator (tPA), continue to be the primary medical intervention for dissolving clots, with ongoing research focused on extending the treatment window for these drugs.

How Is Technology Enhancing Stroke Diagnosis and Treatment?

Technological advancements in imaging and telemedicine are revolutionizing the diagnosis and treatment of acute ischemic stroke. Advanced neuroimaging techniques, such as perfusion imaging, allow for more accurate assessment of brain tissue at risk, helping physicians determine the most appropriate treatment approach. The rise of telemedicine has also enabled remote diagnosis and consultation, allowing stroke specialists to assess patients in real-time, even in rural or underserved areas. This has improved access to timely care, particularly in regions where stroke specialists are not readily available. AI-powered diagnostic tools are further enhancing stroke management by assisting in the early detection of stroke symptoms and helping healthcare professionals make faster, more accurate decisions.

What Is Driving Growth in the Acute Ischemic Stroke Diagnosis and Treatment Market?

The growth in the acute ischemic stroke diagnosis and treatment market is driven by several factors, including the increasing prevalence of stroke, advancements in treatment technologies, and growing awareness of the importance of early diagnosis. The global burden of stroke is rising due to factors such as aging populations, unhealthy lifestyles, and the increasing incidence of conditions like hypertension and diabetes. Innovations in imaging and thrombectomy devices are improving patient outcomes, while the expansion of telemedicine services is increasing access to specialized stroke care. Additionally, public health campaigns focused on raising awareness of stroke symptoms and the importance of early intervention are contributing to the market’s growth.

SCOPE OF STUDY:

The report analyzes the Acute Ischemic Stroke Diagnosis and Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Diagnostic Type (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Cerebral angiography, Nuclear Imaging, Other Diagnostic Types); Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• Bayer AG
• Biogen
• Boehringer Ingelheim
• Boston Scientific Corporation
• Cordis Corporation
• Covidien plc
• Daiichi Sankyo
• GE Healthcare
• Genentech, Inc.
• Hitachi Ltd
• Johnson & Johnson
• Koninklijke Philips N.V.
• Medtronic plc
• Merck & Co., Inc.
• Penumbra, Inc
• Pfizer Inc.
• Philips Healthcare
• Sanofi
• Siemens AG
• Siemens Healthcare
• Stryker Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.